/ Research
CYTOWAVE EUROPE AS
Closed at October 29th, 2024, Voluntary liquidation
Salg og utvikling av bioteknisk utstyr, herunder deltagelse i
medisinsk forskning og formidling av FoU-kompetanse, samt tilknyttede
tjenester og andre produkter, som naturlig faller sammen med dette.
Videre å delta i andre selskaper med lignende virksomhet, kjøp og salg
av aksjer, eller på annen måte gjøre seg interessert i andre
foretagender.
Forskning og utvikling samt introduskjon, salg og markedsføring av
medisinsk utstyr fra CytoWave Technology LLC, USA. Videre
tilretteleggelse av medisinsk forskning innen bioteknologi uten å
begrense seg hertil
Keywords
researchdevelopment worknatural sciencesengineeringtechnologymedicineagricultureinterdisciplinary research
Organization
- Chairman of the board
- Operation time
- 29 years
- - Feb 19, 1995 to Oct 29, 2024
- Type
- Limited company
- VAT registered
- No
- Number of employees
- 0
Ownership
- Number of shares and share classes
- 20,000
- 1 share class
- Total number of shareholders
- 2
- persons
Financials
- Annual total result 2023
- -6,622
- NOK
- Total equity 2023
- -2,597,784
- NOK
Last update: Aug 29, 2024
Management
Board
| Name | Role | Shares |
|---|---|---|
| Chairman | 90 % directly | |
GH | Alternate Member | 10 % directly |
Others
| Name | Role | Shares |
|---|---|---|
| Accountant | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
| Chairman | 90 % directly | |
GH | Alternate Member | 10 % directly |
Last update: Apr 13, 2023
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 18,000 | 90 % | |
GH | Ordinary shares | 2,000 | 10 % |
Last update: May 24, 2024
Financials
in NOK
Summary
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total operating income | 0 | 0 | 0 |
Annual Total Result | -6,622 | -250,658 | -2,522 |
Total assets | 0 | 200 | 247,542 |
Total liabilities | 2,597,784 | 2,591,362 | 2,588,046 |
Total equity | -2,597,784 | -2,591,162 | -2,340,504 |
P&L
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total operating income | 0 | 0 | 0 |
Total operating costs | 6,622 | 3,304 | 2,522 |
Operating result | -6,622 | -3,304 | -2,522 |
Financial income/costs | 0 | -247,355 | 0 |
Profit before tax | -6,622 | -250,658 | -2,522 |
Total tax & extraordinary income/cost | 0 | 0 | 0 |
Annual Total Result | -6,622 | -250,658 | -2,522 |
Balance overview
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total fixed assets | 0 | 0 | 177,560 |
Total current assets | 0 | 200 | 69,982 |
Total assets | 0 | 200 | 247,542 |
Short term debt | 2,597,784 | 2,591,362 | 2,588,046 |
Long term debt | 0 | 0 | 0 |
Total liabilities | 2,597,784 | 2,591,362 | 2,588,046 |
Contributed capital | 2,000,000 | 2,000,000 | 2,000,000 |
Retained earnings | -4,597,784 | -4,591,162 | -4,340,504 |
Total equity | -2,597,784 | -2,591,162 | -2,340,504 |
Total equity and liabilities | 0 | 200 | 247,542 |
Classification
21st company classification
BETA
Small company
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.19
Industrial group
Other research and experimental development on natural sciences and engineering
72.190
Industrial group
Other research and experimental development on natural sciences and engineering